Scarica l'app Stockscreener
2.36
2.88%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$2.43
Aprire:
$2.45
Volume 24 ore:
544.01K
Relative Volume:
0.47
Capitalizzazione di mercato:
$253.51M
Reddito:
$42.51M
Utile/perdita netta:
$-116.49M
Rapporto P/E:
-2.1071
EPS:
-1.12
Flusso di cassa netto:
$-120.82M
1 W Prestazione:
-4.45%
1M Prestazione:
-23.38%
6M Prestazione:
-77.31%
1 anno Prestazione:
-78.66%
Intervallo 1D:
$2.35
$2.50
Intervallo di 1 settimana:
$2.35
$2.62
Portata 52W:
$2.35
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta TNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
2.36 | 253.51M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan
Tango Therapeutics executive sells shares worth $43,865 - MSN
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat
Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat
Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat
Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat
Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance
What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia
Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia
Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN
Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News
TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle
Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha
TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times
Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
Cantor Fitzgerald Estimates TNGX FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts TNGX FY2025 Earnings - MarketBeat
Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St
Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks
Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat
Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tango Therapeutics Inc Azioni (TNGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 06 '24 |
Sale |
3.28 |
1,494,558 |
4,896,023 |
11,836,178 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):